← All trials
NCT04836260
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 8, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Apr 8, 2021
- Last posted
- Apr 8, 2021
- Enrollment
- 100
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GenevaLead sponsor
- University of BaselCollaborator
- University of GenevaReponsible party - principal investigator
- University of GenevaOverall official - principal investigator
- Hôpital FribourgeoisCollaborator
- HFR-Fribourg Hôpital CantonalOverall official - principal investigator
- Klinik Infektiologie & SpitalhygieneOverall official - principal investigator
- Ospedale Regionale di LuganoOverall official - principal investigator
- Ospedale Regionale di LuganoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.